H.C. Wainwright has revised its price target for Citius Pharmaceuticals (CTXR, Financial), reducing it significantly from $100 to $4. Despite this adjustment, the firm maintains a Buy rating on the stock.
This decision follows Citius Pharmaceuticals' recent execution of a one-for-25 reverse stock split. The company is projected to commercialize two key therapies, Mino-Lok and Lymphir, by the first half of 2026. The analyst believes that the current share price does not fully reflect the potential value of these products. Investors are advised to consider the long-term prospects of these therapies, which may offer substantial benefits to the company’s growth trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Citius Pharmaceuticals Inc (CTXR, Financial) is $8.50 with a high estimate of $9.00 and a low estimate of $8.00. The average target implies an upside of 785.42% from the current price of $0.96. More detailed estimate data can be found on the Citius Pharmaceuticals Inc (CTXR) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Citius Pharmaceuticals Inc's (CTXR, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
